8-KOther EventsExhibits & Filings

THERMO FISHER SCIENTIFIC INC. 8-K Report, Corporate Update (Aug 29, 2017)

Filed August 29, 2017For Securities:TMO

Summary

Thermo Fisher Scientific Inc. (TMO) has filed an 8-K report to announce the expiration and results of a tender offer conducted by its wholly owned subsidiary, Thermo Fisher (CN) Luxembourg S.à r.l. This tender offer was for all outstanding ordinary shares of Patheon N.V. The filing itself primarily serves to incorporate by reference a press release dated August 29, 2017, which contains the detailed results of this significant acquisition activity. For investors, this filing signifies the culmination of an important strategic move to acquire Patheon N.V. The success of the tender offer, as detailed in the accompanying press release, is crucial for understanding the potential integration and future performance of the combined entity. Investors should review the referenced press release for specifics on the offer's acceptance rate, pricing, and the immediate implications for Thermo Fisher's ownership and control of Patheon.

Key Highlights

  • 1Thermo Fisher Scientific (TMO) announced the expiration and results of its tender offer for Patheon N.V. ordinary shares.
  • 2The tender offer was conducted through TMO's wholly owned subsidiary, Thermo Fisher (CN) Luxembourg S.à r.l.
  • 3This filing formally incorporates a press release dated August 29, 2017, which details the outcome of the tender offer.
  • 4The acquisition of Patheon N.V. is a significant strategic development for Thermo Fisher.
  • 5Investors should refer to the attached press release (Exhibit 99.1) for detailed results and implications.

Frequently Asked Questions

The main purpose of this 8-K filing is to formally announce the expiration and results of Thermo Fisher Scientific's tender offer to acquire all outstanding ordinary shares of Patheon N.V. It incorporates a press release with the detailed information.

The tender offer was made by Thermo Fisher (CN) Luxembourg S.à r.l., which is a wholly owned subsidiary of Thermo Fisher Scientific Inc.

The detailed results of the tender offer are provided in the press release dated August 29, 2017, which is attached as Exhibit 99.1 to this 8-K filing and incorporated by reference.

While this specific filing focuses on the tender offer results, the acquisition of Patheon N.V. is a significant strategic move for Thermo Fisher, likely aimed at expanding its capabilities, market reach, or service offerings within the life sciences and healthcare sectors. Investors should consult the press release for any specific strategic rationale mentioned.